Double transplant strategy targets tough lymphoma

NCT ID NCT00882895

Ongoing Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests a two-step transplant approach for people with high-risk non-Hodgkin's lymphoma. First, patients receive a transplant using their own stem cells, followed by a second transplant from a donor. The goal is to improve long-term disease control. The trial enrolled 18 adults aged 18 to 70 with aggressive or relapsed lymphoma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stem cell transplant (autologous followed by non-myeloablative allogeneic)
What this could lead to: If it works, this two-step transplant approach could offer better long-term control of high-risk non-Hodgkin's lymphoma.
What could go wrong: This is a small, early-phase trial with only 18 participants, so results may not apply broadly. The procedure carries risks like graft-versus-host disease and infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, NON-HODGKIN

Contacts and locations

Locations

Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.